Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

被引：47
|
作者：
Ulhaq, Zulvikar Syambani [1 ]
Soraya, Gita Vita [2 ]
机构：
[1] Maulana Malik Ibrahim Islamic State Univ Malang, Dept Biochem, Fac Med & Hlth Sci, Batu 65151, East Java, Indonesia
[2] Hasanuddin Univ, Dept Biochem, Fac Med, Makassar 90245, South Sulawesi, Indonesia
来源：
MEDICINA CLINICA | 2020年 / 155卷 / 12期
关键词：
OFF-LABEL USE; TOCILIZUMAB; INTERLEUKIN-6;
D O I：
10.1016/j.medcli.2020.07.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：548 / 556
页数：9
相关论文
共 50 条
  • [21] Anti-IL-6 receptor antibody therapy for autoimmune diseases
    Ishikawa, N. Nishimoto.
    Lee, H.
    Aoki, C.
    Mima, T.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2009, 301 (01) : 44 - 44
  • [22] A humanized anti-IL-6 receptor antibody for the treatment of chronic inflammatory diseases
    Yoshizaki, K.
    Nakazawa, S.
    Nishikawa, T.
    Tanigawa, M.
    Ito, H.
    CYTOKINE, 2012, 59 (03) : 571 - 571
  • [23] Effects of anti-IL-6 receptor antibody on human monocytes
    Tono, Toshihiro
    Aihara, Satoko
    Hoshiyama, Takayuki
    Arinuma, Yoshiyuki
    Nagai, Tatsuo
    Hirohata, Shunsei
    MODERN RHEUMATOLOGY, 2015, 25 (01) : 79 - 84
  • [24] Editorial: Tocilizumab, a Humanized Therapeutic IL-6 Receptor (IL-6R) Monoclonal Antibody, and Future Combination Therapies for Severe COVID-19
    Parums, Dinah V.
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [25] IL-6 antagonists in COVID-19
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2021, 3 (10): : E688 - E688
  • [26] An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
    Saavedra, Danay
    Ane-Kouri, Ana Laura
    Sanchez, Naivy
    Filgueira, Lazaro Manuel
    Betancourt, Julio
    Herrera, Carlos
    Manso, Leniel
    Chavez, Elibet
    Caballero, Armando
    Hidalgo, Carlos
    Lorenzo, Geydi
    Cepeda, Meylan
    Valenzuela, Carmen
    Ramos, Mayra
    Leon, Kalet
    Mazorra, Zaima
    Crombet, Tania
    IMMUNITY & AGEING, 2020, 17 (01)
  • [27] Role of interleukin-6 (IL-6) in platelet production: extension of a quantitative systems pharmacology model (QSPM) to describe anti-IL-6 and anti-IL-6 receptor therapies
    Koride, Sarita
    Nayak, Satyaprakash
    Banfield, Christopher
    Peterson, Mark C.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S102 - S102
  • [28] An anti-CD6 monoclonal antibody (itolizumab) reduces circulating IL-6 in severe COVID-19 elderly patients
    Danay Saavedra
    Ana Laura Añé-Kourí
    Naivy Sánchez
    Lázaro Manuel Filgueira
    Julio Betancourt
    Carlos Herrera
    Leniel Manso
    Elibet Chávez
    Armando Caballero
    Carlos Hidalgo
    Geydi Lorenzo
    Meylan Cepeda
    Carmen Valenzuela
    Mayra Ramos
    Kalet León
    Zaima Mazorra
    Tania Crombet
    Immunity & Ageing, 17
  • [29] Protective effects of anti-IL-6 antibody treatment in sepsis
    Neff, TA
    Riedemann, NC
    Guo, RF
    Laudes, I
    Sarma, V
    Ward, PA
    FASEB JOURNAL, 2002, 16 (04): : A592 - A592
  • [30] The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart
    Perricone, C.
    Conigliaro, P.
    Ciccacci, C.
    Marcucci, E.
    Cafaro, G.
    Bartoloni, E.
    Perricone, R.
    Novelli, G.
    Borgiani, P.
    Gerli, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020, 38 (03) : 580 - 580
12345